Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.
about
The life and times of the EnterococcusEmergence of vancomycin-resistant enterococciCeftriaxone therapy of serious bacterial infections in adults.Therapeutic effects of cefpirome (HR 810) on experimental mixed infections with Enterococcus faecalis and Escherichia coli in mice.A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.Changes in endogenous microflora among febrile granulocytopenic patients receiving empiric antibiotic therapy: implications for fungal superinfection.Colonization and infection with Enterococcus faecalis in intensive care units: the role of antimicrobial agentsEffect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patientsTimentin versus piperacillin or moxalactam in the therapy of acute bacterial infections.Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremiaDouble-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infectionsImipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections.Evaluation of aztreonam in the treatment of severe bacterial infections.Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections.A prospective randomized trial of imipenem-cilastatin versus clindamycin/tobramycin in the treatment of intra-abdominal and pelvic infectionsIn vitro activity, efficacy, and pharmacology of moxalactam, a new beta-lactam antibioticClinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections.Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings.Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.Comparison of moxalactam and gentamicin in the treatment of complicated urinary tract infections.Imipenem versus moxalactam in the treatment of serious infections.Interaction of cefotaxime and aminoglycosides against enterococci in vitro.Infections in intensive care patients: use of new B-lactams.Clinical implications of positive blood cultures.Pathogenicity of the enterococcus in surgical infections.Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus.The enterococcus.Clinical evaluation of moxalactam.New antibiotics. New hopes and new problems.Spheroplast induction in clinical isolates of Serratia marcescens in the presence of Ca2+ or Mg2+.The third generation cephalosporins.Pathogenicity of enterococci outside of urinary tract and blood stream.Enterococcal superinfection and colonization with aztreonam therapy.Effect of imipenem-cilastatin therapy on fecal flora.Impact of cefoperazone therapy on fecal floraMicroorganisms and diarrhea in enterally fed intensive care unit patients.Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults.Toxic and adverse reactions encountered with new beta-lactam antibiotics.The great cephalosporin wars.In vitro assessment of urinary isolates of ampicillin-resistant enterococci.
P2860
Q24616875-AF2CD123-F02B-4BED-884D-6E891C07EF5EQ28362182-427518E9-4888-4C61-A283-1D0DD6F3C899Q33476936-D25D6B54-53DC-420C-8688-88450F7D8600Q34031360-794E9966-B314-4368-A4AB-B9F9F950F160Q34707883-A9C814BD-E681-44B9-A86C-05088AFBE816Q34734184-700E04C6-7CB8-44F0-B852-1660DF0CEDA9Q35121010-17AE0050-25D7-4384-9BAD-F5EB125E04A3Q35207941-F9D2B90E-B63B-4CA2-9F71-B69F69F7659DQ35568199-79CCD892-35C6-4055-A55A-ECAD744C6CBDQ35571259-A17142DA-8FFB-4965-AB5D-54E178E8B146Q35574202-73CED0B9-2CF7-451A-A548-D8342DB61770Q35640457-E84AF380-C5B7-4D64-8725-39DFF7358423Q35646167-18AA43FD-DF78-4F03-8015-135ECB65498BQ35646344-CFFB50F3-AC15-4408-87D5-23C830BE75E6Q35649774-8B4F21C2-AF6C-4FC0-A8AB-B615069CC51FQ35672113-4F2260CD-2429-465F-9E36-021A2C736ACFQ35674991-DB56E611-3422-4FF6-832C-0BD8815867CCQ35742444-B1FB95D6-6838-4CC5-8E6C-12B21DFD2E98Q35749310-4342E52B-C71A-4C0F-90BF-B63B7C10C890Q35754903-9368AB6B-D355-4586-94B6-BFD14EF080E4Q35755479-F9488B5C-B275-4C76-9A05-BD5499D7C3F9Q35755495-F66E5B45-19C9-4FCD-8FF1-6F268B0C53F8Q35876703-AAA4FB8D-E465-4862-AB1B-F937C242DA1DQ36635540-FD55A531-C517-4608-829E-752C8523DA32Q37943271-89CE36DD-8E28-4822-94DD-9865B9BE216FQ38591480-07AE320D-BCAA-402D-A3AD-C586B30F1849Q39592494-74C85918-01AD-436F-9AFB-ACD0853EB9E8Q39857079-3CD76FF5-549E-41FE-886E-89341A3DB9F4Q40178076-E66E261F-1F54-4DC6-AA27-E0670AEBA554Q40209444-B02E7172-53A7-44AB-8E27-B72B848D515CQ40253708-49D1FBEE-CFE8-464A-85D0-50950DC89878Q40265930-71A6306F-8CA8-41C2-BA1B-05865CA583DDQ40283424-ADF6D560-65F6-44F9-B2D9-D9F27DA2BCADQ40283458-19650F18-0CE4-441F-A790-590FAFE3ABA1Q41808443-41CAA539-0B0B-433E-ACBE-280346EB0E1BQ42115235-2CD9E994-9359-4E8A-9B46-7B1806A7A205Q42248639-627CB475-DBCE-491D-BF81-44DC87B0F599Q42667192-04519BB2-B38E-41BF-8D3F-9EA8C59784EAQ43882306-160BEC81-B7A3-44DD-809F-C8E7FACB9C41Q43888392-2FFE9B05-E301-41AF-8EBC-F3DF175581C0
P2860
Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh
1981年學術文章
@zh-hant
name
Enterococcal superinfection an ...... new broad-spectrum antibiotic.
@en
Enterococcal superinfection an ...... new broad-spectrum antibiotic.
@nl
type
label
Enterococcal superinfection an ...... new broad-spectrum antibiotic.
@en
Enterococcal superinfection an ...... new broad-spectrum antibiotic.
@nl
prefLabel
Enterococcal superinfection an ...... new broad-spectrum antibiotic.
@en
Enterococcal superinfection an ...... new broad-spectrum antibiotic.
@nl
P1476
Enterococcal superinfection an ...... new broad-spectrum antibiotic.
@en
P2093
P304
P356
10.7326/0003-4819-94-6-784
P407
P577
1981-06-01T00:00:00Z